Reviva Pharmaceuticals' CEO will present at the Oppenheimer Healthcare Life Sciences Conference on February 12, 2025.
Quiver AI Summary
Reviva Pharmaceuticals Holdings, Inc. announced that its Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference held virtually from February 11-12, 2025. During the presentation scheduled for February 12 at 2:40 p.m. ET, Bhat will provide a corporate update on Reviva's ongoing work in developing therapies for unmet medical needs, particularly in central nervous system, inflammatory, and cardiometabolic diseases. Reviva's pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered by the company and protected by composition of matter patents in multiple regions.
Potential Positives
- Reviva Pharmaceuticals will present at the prestigious Oppenheimer 35th Annual Healthcare Life Sciences Conference, highlighting visibility and potential investor interest in the company.
- The presentation will include a corporate update, which may enhance transparency regarding Reviva's developments and strategies in the pharmaceutical sector.
- Reviva has two drug candidates in its pipeline, brilaroxazine and RP1208, both of which are new chemical entities and have received composition of matter patents in key markets.
Potential Negatives
- Announcement of the company's participation in a conference may suggest a lack of significant new developments or updates, as the focus is on a corporate update rather than major product news or breakthroughs.
- The lack of detailed information about ongoing trials or progress in their drug development pipeline could indicate potential stagnation or challenges in advancing their therapeutics.
- The phrasing of “unmet medical needs” could imply that existing treatments in the market are inadequate, thereby raising concerns over the effectiveness and marketability of the company's own drug candidates.
FAQ
What is the purpose of Reviva Pharmaceuticals?
Reviva Pharmaceuticals focuses on developing therapies for unmet medical needs in CNS, inflammatory, and cardiometabolic diseases.
Who is presenting at the Oppenheimer Conference?
Laxminarayan Bhat, Ph.D., the Founder, President, and CEO of Reviva, will present at the conference.
When will the Oppenheimer 35th Annual Healthcare Life Sciences Conference take place?
The conference will be held virtually on February 11-12, 2025.
What drug candidates are in Reviva's pipeline?
Reviva's pipeline includes brilaroxazine (RP5063) and RP1208, both new chemical entities discovered in-house.
What are the patent statuses for Reviva's drug candidates?
Reviva has been granted composition of matter patents for brilaroxazine and RP1208 in the U.S., Europe, and other countries.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
CUPERTINO, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the Oppenheimer 35 th Annual Healthcare Life Sciences Conference, taking place virtually February 11-12, 2025.
Oppenheimer 35
th
Annual Healthcare Life Sciences Conference
Format: Corporate update
Date: Wednesday, February 12, 2025
Time: 2:40 p.m. ET
Location: Virtual
Webcast Link:
Click Here
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
[email protected]